Joining forces to improve health worldwide
Our work at BioNTech is driven by data and a clear vision: To translate science into first-in-class and best-in-class medicines for people worldwide. We endeavor to usher in a new era of immunotherapy to address cancer, infectious diseases, as well as a growing list of other serious conditions. In our journey to deliver therapies for a healthier tomorrow, we have successfully established a network of world-class corporate and scientific partnerships.
If your team is interested in collaborating with us, please contact us to learn about partnering and collaboration opportunities.
Alongside our industry-leading partners, we work on bringing novel therapies to the patients who need them most.
In February 2024, we entered into a strategic collaboration with Autolus Therapeutics to advance both companies’ autologous CAR-T programs toward commercialization. We also entered into a license and option agreement with Autolus which grants us various rights, including the option to utilize Autolus’ commercial and clinical site network, manufacturing capacities and commercial supply infrastructure to support the clinical development of BNT211 in CLDN6+ tumors. We have agreed to support the launch and expansion of Autolus’ lead cell therapy candidate, obe-cel in exchange for potential royalty payments. In addition, we have the option to access a suite of Autolus target binders and cell programming technologies to support our development of in vivo cell therapy and antibody-drug conjugate candidates.
For more information on our CAR-T platform, click here.
Bill & Melinda Gates Foundation
In September 2019, we entered into a partnership with the Bill & Melinda Gates Foundation to develop HIV and tuberculosis programs based on our proprietary mRNA vaccine technology. The investment was the largest equity investment made by the Foundation’s Strategic Investment Fund to date. The collaboration comprises identification and pre-clinical development of vaccines and immunotherapies for these infectious diseases and strives to provide affordable access to world-class medicines in developing countries. The collaboration may also be extended to other infectious disease indications.
In October 2023, we signed a license and collaboration agreement with Biotheus to develop BNT327/PM8002, a bispecific antibody candidate targeting PD-L1 and Vascular Endothelial Growth Factor (“VEGF”). As part of the collaboration, we hold the rights for the worldwide development, manufacturing and commercialization globally, excluding Mainland China, Hong Kong SAR, Macau SAR and Taiwan region, where Biotheus retains the rights to the candidate. The collaboration is intended to support our aim to leverage our next-generation immunomodulators to unlock potential in novel patient populations.
For more information on our antibody platforms, click here.
Coalition for Epidemic Preparedness Innovations (CEPI)
In September 2023, we entered into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of an mRNA-based vaccine candidate for the prevention of mpox. The partnership is part of our strategy to develop novel prophylactic vaccines for the prevention of infectious diseases with high medical need, including diseases that are disproportionally prevalent in lower-income countries. It will also contribute to CEPI’s 100 Days Mission, a global effort to accelerate the development of well-tolerated and effective vaccines against potential future pandemic viruses.
For more information on our mRNA-based vaccine candidates, click here.
In January 2022, we entered into a multi-target discovery collaboration with Crescendo Biologics to develop novel immunotherapies for the treatment of patients with cancer and other diseases. Utilizing Crescendo’s proprietary Humabody® VH platform, we aim to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against select targets. Their specific properties and modular structure makes Humabodies ideally suited for the development of multi-target immunotherapies.
In April 2023, we formed a global strategic partnership with Duality Biologics to accelerate the development of differentiated antibody-drug conjugate (ADC) therapeutics for solid tumors. This agreement further expands our clinical-stage oncology portfolio with a new class of precision medicine therapeutics expanding the breadth of our immunotherapy toolkit with synergistic potential. As part of the collaboration, we added three topoisomerase-1 inhibitor-based ADC candidates to our pipeline: BNT323/DB-1303, BNT324/DB-1311, and BNT325/DB-1305. The lead candidate, BNT323/DB-1303, entered pivotal Phase 3 evaluation in patients with metastatic breast cancer in January 2024.
For more information on our ADC platform, click here.
On 16 March 2020, BioNTech and Fosun Pharma announced a strategic collaboration to develop and commercialize COVID-19 vaccines based on BioNTech’s mRNA technology platform for the Greater China Market including the Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region. The mRNA COVID-19 vaccine has been granted Emergency Use Application in Hong Kong SAR (January 2021) and Special Import Authorizations in Macau SAR (February 2021) and the Taiwan region (July 2021) and in December 2022, we provided approximately 11,500 COVID-19 vaccine doses to enable a vaccination campaign for German expatriates in Mainland China.
For more information on our mRNA vaccine platform, click here.
In September 2016, we embarked on a pioneering collaboration with Genentech, a member of the Roche group, to jointly research, develop, manufacture and commercialize individualized mRNA-based vaccines targeting cancer neoantigens specific to individual patients: individualized Neoantigen Specific Immunotherapy (iNeST). This effort includes our iNeST development candidate autogene cevumeran BNT122, which is currently being evaluated in two jointly-conducted clinical trials for advanced melanoma and advanced/metastatic solid tumors, respectively. Under the partnership, BioNTech also began a colorectal cancer Phase 2 trial in October 2021 which utilizes an individualized approach.
For more information on our mRNA-based iNeST platform, click here.
In July 2018, we formed a strategic partnership with Genevant for the development of certain mRNA-based protein replacement therapies. The collaboration also includes certain exclusive licenses to Genevant’s lipid nanoparticle (LNP) drug delivery technology for mRNA-based products directed to specified oncology targets.
For more information on our protein replacement platform for rare diseases, click here.
In May 2015, we entered into a license and collaboration agreement with Genmab to jointly research, develop and commercialize novel mono- and bispecific cancer antibodies with superior in vivo efficacy, fusing our proprietary immunomodulatory antibodies and Genmab’s DuoBody® technology platform or HexaBody® technology platform. The collaboration was expanded in 2016 to include additional targets and technologies as well as in 2022 to include novel monospecific antibody candidates for various cancer indications. We are currently evaluating five product candidates in various cancer indications in clinical trials. Our lead product candidate, BNT311/GEN1046, entered clinical evaluation in multiple solid tumors in June 2019 and is currently being evaluated in two additional Phase 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC) and endometrial cancer.
For more information on our next-generation checkpoint immunomodulators platform, click here.
In February 2022, we entered into a 3-year, multi-target research collaboration with Medigene to develop T cell receptor (TCR) based immunotherapies against cancer. Medigene’s automated, high-throughput TCR discovery platform will be leveraged to discover and develop innovative TCR immunotherapies against solid tumor targets selected by BioNTech. The agreement includes the acquisition of Medigene’s next generation preclinical PRAME TCR program and licenses to their PD1-41BB switch receptor and precision pairing technologies.
For more information on our TCR platform, click here.
In October 2023, we entered into a strategic research collaboration and worldwide license agreement with MediLink Therapeutics to develop the next-generation ADC candidate BNT326/YL202. The candidate is directed against Human Epidermal Growth Factor Receptor 3 (“HER3”), a target linked to the aggressive growth and spread of cancer cells. We have exclusive global rights for the development, manufacturing, and commercialization of BNT326/YL202, excluding Mainland China, Hong Kong Special Administrative Region (“SAR”), and Macau SAR.
For more information on our ADC platform, click here.
In March 2023, we entered into a license and collaboration agreement to co-develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications. In addition, we also plan to combine ONC-392 with our proprietary oncology product candidates to evaluate complementary modes of action with the aim to increase therapeutic effect and unlock larger patient populations. For more information on our next-generation checkpoint immunomodulators platform, click here.
Together with our partner Pfizer, we developed the first FDA approved mRNA-based vaccine and the first COVID-19 vaccine in history, in an unprecedented development timeline. The renowned success of our COVID-19 collaboration, initiated in March 2020, was built on the strength of our existing partnership for the development of a mRNA-based influenza vaccine (BNT161) announced in August 2018. To expand the infectious disease partnership, we signed a development and commercialization collaboration with Pfizer to develop the first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV).
For more information on our mRNA vaccine platform, click here.
In July 2020, we began a strategic collaboration with Regeneron to jointly conduct a Phase 2 clinical trial combining our proprietary mRNA-based FixVac vaccine candidate, BNT111, and Regeneron’s Libtayo® (cemiplimab), an anti-PD-1 therapy for the treatment of advanced melanoma. The Phase 2 trial was initiated in June 2021 and BNT111 received Orphan Drug Designation by the FDA and FDA Fast Track Designation later that same year.
In March 2022, we announced the expansion of our strategic collaboration with Regeneron. Under the agreement, the combination of our FixVac product candidate BNT116 and Libtayo is expected to be advanced into clinical development for the treatment of advanced non-small-cell lung cancer (NSCLC). The first-in-human clinical trial is intended to evaluate the safety, tolerability and preliminary efficacy of BNT116 alone and in combination with Libtayo.
For more information on our mRNA-based FixVac platform, click here.
In November 2022, we entered into a multi-target research collaboration with Ryvu Therapeutics for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING agonist portfolio as standalone small molecules. The collaboration consists of two parts: BioNTech has a global, exclusive license to develop and commercialize Ryvu’s STING agonist portfolio as standalone small molecules, including as monotherapy and in therapeutic combinations. In addition, BioNTech and Ryvu jointly undertake drug discovery and research projects to develop multiple small molecule programs directed at exclusive targets selected by BioNTech, primarily focused on immune modulation within oncology, with potential applications in other disease areas.
For more information on our small molecule immunomodulators, click here.
In June 2015, we initiated a strategic partnership with Siemens to construct a fully automated, paperless and digitalized commercial cGMP-production site for individualized vaccines. The partnership was expanded in response to the COVID-19 vaccine program as Siemens supported the rapid upscaling of production capacities in our Marburg facility, which is now a model for new manufacturing sites around the world.
For more information on our comprehensive manufacturing capabilities, click here.
BioNTech collaborates with a large number of universities and medical centers in Europe and the U.S. to discover and develop new immunotherapies.
Ci3 is a scientific, clinical and regulatory network of over 500 scientists committed to advancing “new to the world” immunotherapies.
The DZIF (German Center for Infection Research) aims to bridge the gaps between the discovery of new treatment approaches, preclinical development and clinical testing.
TRON is a biopharmaceutical research organization that pursues the development of new diagnostics and drugs to treat cancer and other severe diseases. TRON was founded to facilitate clinical translation of innovative science by interfacing between public and private stakeholders and bridging the gap between research insight and mature product development.
University of Pennsylvania
In October 2018, we entered into a research collaboration with the University of Pennsylvania that provides us with the exclusivity to develop and commercialize mRNA immunotherapies for the treatment of up to 10 infectious disease indications with BNT163 entering the clinic in in December 2022. BNT163 is an HSV vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1.